2023-2024 Key Trends And Updates: Securities Litigation Against Life Sciences Companies Webinar – Life Sciences, Biotechnology & Nanotechnology

In this webinar, Caroline Bullerjahn, Tucker DeVoe, and Justin Ward from Goodwin, and Frank Schneider from Cornerstone Research will
discuss key updates and recent trends concerning securities class
actions filed against publicly traded pharmaceutical,
biotechnology, medical device and healthcare product and services
companies (collectively, “life sciences companies”),
which continue to be a primary target of the plaintiffs’ bar.
While securities class action litigation against life sciences
companies decreased slightly in 2023 compared to 2022, life
sciences companies remain by far the most targeted sector for these
suits, and the total number of securities class action suits filed
against life sciences companies remains above the long-run
historical average (40 filings in 2023 compared to 37 filings per
year in from 1997-2022).

In addition to analyzing these overall trends, we will:

• examine data for class action filings in 2023 and trends based
  upon such data, focusing on filings against life sciences
  companies;




• review several significant, impactful recent decisions issued
  by federal courts particularly relevant to life sciences
  companies;




• provide in-depth analysis of the potential implications of
  these decisions, which involve challenges that life sciences
  companies often face; and




• discuss practical steps you can take to make informed choices
  related to your business, including your public disclosures.

This program is pending one hour CLE credit in California,
New York, New Jersey, and/or Pennsylvania.

This webinar is scheduled for Wednesday, April 3^rd
from 2:30 – 3:30 PM ET. Please register here.

The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.